Skip to content
Screener

Summit Therapeutics SMMT Q2 2025 earnings

Reported August 11, 2025 · After market close

EPS-$0.76Miss by $0.67
EPS estimate-$0.09

Next report

Oct 19, 2026 (in 2 months)
Revenue estimate$71.4K
EPS estimate-$0.28

Financials

Q2 2025

Income statement

See full
Net income-$565.7M-837%
EPS (diluted)-$0.76-744%

Balance sheet

See full
Cash & equivalents$4.3M-72.8%
Total debt$5.6M-36.2%
Total equity$259.4M+33.0%
Total assets$324.0M-5.2%

Cash flow

See full
Operating cash flow-$66.7M-102%
CapEx--100%
Free cash flow-$66.7M-102%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$15.54B+180%
Enterprise value$15.54B+181%

Returns & leverage

See full
Return on equity-328.3%-603pp
Debt / equity0×0.0×
Current ratio5.1×+2.8×

FAQ

When did Summit Therapeutics report Q2 2025 earnings?
Summit Therapeutics (SMMT) reported Q2 2025 earnings on August 11, 2025 after market close.
What were Summit Therapeutics's Q2 2025 revenue and EPS?
Summit Therapeutics reported eps of $-0.76 for Q2 2025.
Did Summit Therapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.09 by $0.67.
How did Summit Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 1420.0% from $-0.05.
Where can I find Summit Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001599298-25-000128) and the 10-Q periodic report (0001599298-25-000126) directly on SEC EDGAR. The filing index links above go to sec.gov.